Market news

Evolent Health’s second quarter results drew a significant positive market reaction, reflecting outperformance versus Wall Street’s expectations on both revenue and profitability. Management pointed to the successful launch of the Highmark contract and robust customer renewals as key drivers. CEO Seth Blackley specifically highlighted that clinical engagement metrics for new partnerships, such as Aetna and Highmark, were trending above target, signaling strong execution in the company’s core val

Detailed price information for Evolent Health Inc Cl A Com (EVH-N) from The Globe and Mail including charting and trades.

Detailed price information for Evolent Health Inc Cl A Com (EVH-N) from The Globe and Mail including charting and trades.

Evolent Health (EVH) has an average rating of buy and mean price target of $5.62, according to analy

Evolent Health (EVH) has an average rating of buy and mean price target of $5.96, according to analy

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on year to $652.5 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $0.02 per share was significantly above analysts’ consensus estimates.

Detailed price information for Evolent Health Inc Cl A Com (EVH-N) from The Globe and Mail including charting and trades.

Detailed price information for Evolent Health Inc Cl A Com (EVH-N) from The Globe and Mail including charting and trades.

Evolent Health (EVH) delivered earnings and revenue surprises of +300.00% and +6.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Motley Fool Press Release.

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on year to $652.5 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $0.02 per share was significantly above analysts’ consensus estimates.

Evolent Health: Q2 Earnings Snapshot

Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2026.

Evolent Health Earnings: What To Look For From EVH

Shares of healthcare solutions company Evolent Health (NYSE:EVH) fell 13% in the afternoon session after Wall Street firm Citi downgraded the company's stock from Buy to Neutral. Despite raising the price target from $5.50 to $6.75, the investment firm reassessed the stock's potential, citing a less attractive risk-to-reward setup following a recent price increase. Analysts highlighted uncertainties surrounding healthcare exchange dis-enrollment and shifts in patient care needs. Additionally, Ci

Evolent Health (EVH) has an average rating of buy and mean price target of $5.96, according to analy

Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before market open, with a conference call to follow at 8 a.m. ET.